Figure 3 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

A, Median number of total expanded T-cell clones by response across the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms, and all of the tremelimumab-containing arms combined. B, Proportion of participants with >32 expanded T-cell clones in the durvalumab plus bevacizumab, durvalumab monotherapy, T75 + D, STRIDE, and tremelimumab monotherapy arms. For panel A, P values were derived from a Wilcoxon test comparing response arms. Statistical analysis included nonevaluable participants (zero value total expanded T-cell clones). The lower and upper hinges of each boxplot are at the first and third quartiles. Boxplot whiskers extend to the most extreme value no further than 1.5 × IQR. Horizontal bar in each boxplot is at the median value. For panel B, the proportion of responders who either had more or less than or equal to the durvalumab median of 32 clones is shown. Analysis data cutoff: November 06, 2020. D, durvalumab monotherapy; NA, not available; T, tremelimumab monotherapy.